Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

被引：0

作者：

M. Lefort

S. Sharmin

J. B. Andersen

S. Vukusic

R. Casey

M. Debouverie

G. Edan

J. Ciron

A. Ruet

J. De Sèze

E. Maillart

H. Zephir

P. Labauge

G. Defer

C. Lebrun-Frenay

T. Moreau

E. Berger

P. Clavelou

J. Pelletier

B. Stankoff

O. Gout

E. Thouvenot

O. Heinzlef

A. Al-Khedr

B. Bourre

O. Casez

P. Cabre

A. Montcuquet

A. Wahab

J. P. Camdessanché

A. Maurousset

H. Ben Nasr

K. Hankiewicz

C. Pottier

N. Maubeuge

D. Dimitri-Boulos

C. Nifle

D. A. Laplaud

D. Horakova

E. K. Havrdova

R. Alroughani

G. Izquierdo

S. Eichau

S. Ozakbas

F. Patti

M. Onofrj

A. Lugaresi

M. Terzi

P. Grammond

F. Grand’Maison

机构：

[1] Univ Rennes,Arènes

[2] EHESP, UMR 6051, RSMS (Recherche sur les Services et Management en Santé)

[3] CNRS, U 1309

[4] Inserm,Department of Medicine

[5] Univ Rennes,Melbourne MS Centre, Department of Neurology

[6] CHU Rennes,Department of Neurology

[7] Investigation Clinique de Rennes)],Service de Neurologie, Sclérose en Plaques, Pathologies de La Myéline Et Neuro

[8] University of Melbourne,Inflammation

[9] Royal Melbourne Hospital,Centre Des Neurosciences de Lyon, UMR5292

[10] The Danish Multiple Sclerosis Registry,Centre Hospitalier Régional Universitaire de Nancy

[11] Copenhagen University Hospital,Centre Hospitalier Universitaire de Rennes

[12] Hôpital Neurologique Pierre Wertheimer,Centre Hospitalier Universitaire de Toulouse

[13] Hospices Civils de Lyon,Centre Hospitalier Universitaire de Bordeaux

[14] Observatoire Français de La Sclérose en Plaques,Service des maladies inflammatoires du système nerveux – neurologie, centre d’investigation clinique de Strasbourg

[15] INSERM,Assistance Publique Des Hôpitaux de Paris

[16] Université,Centre Hospitalier Universitaire de Lille

[17] Claude Bernard Lyon 1,Centre Hospitalier Universitaire de Montpellier

[18] Faculté de médecine Lyon Est,Centre Hospitalier Universitaire de Caen Normandie

[19] Eugene Devic EDMUS Foundation,Centre Hospitalier Universitaire de Nice

[20] Hôpital Central,Centre Hospitalier Universitaire Dijon Bourgogne

[21] Hôpital Pontchaillou,Centre Hospitalier Régional Universitaire de Besançon

[22] Hôpital Purpan,Service de Neurologie

[23] CRC-SEP,Assistance Publique Des Hôpitaux de Paris

[24] Hôpital Pellegrin,Centre Hospitalier Universitaire de Martinique

[25] Hôpitaux Universitaire de Strasbourg,Centre Hospitalier Universitaire Limoges

[26] Hôpital de Hautepierre,Assistance Publique Des Hôpitaux de Paris

[27] Hôpital de La Pitié-Salpêtrière,Centre Hospitalier Universitaire de Poitiers

[28] Hôpital Salengro,Assistance Publique Des Hôpitaux de Paris

[29] Hôpital Gui de Chauliac,Centre Hospitalier de Versailles

[30] Hôpital Côte de Nacre,Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine

[31] UR2CA-URRIS,Division of Neurology, Department of Medicine

[32] ,GF Ingrassia Department

[33] Université Nice Côte d’Azur,Department of Neuroscience, Imaging, and Clinical Sciences

[34] Hôpital,Dipartimento Di Scienze Biomediche E Neuromotorie

[35] Hôpital François Mitterrand,Medical Faculty

[36] Maladies Inflammatoires du Système Nerveux Et Neurologie Générale,Nehme and Therese Tohme Multiple Sclerosis Center

[37] Hôpital Jean Minjoz,Department of Basic Medical Sciences, Neuroscience and Sense Organs

[38] Centre Hospitalier Universitaire de Clermont-Ferrand,School of Medicine and Public Health

[39] Hôpital Gabriel-Montpied,Department of Neurology

[40] Aix Marseille Univ,Department of Neuroscience

[41] APHM,Department of Medicine and Surgery

[42] Hôpital de La Timone,Department of Emergency and General Medicine

[43] Hôpital Saint-Antoine,Department of Neurology, Faculty of Medicine

[44] Fondation Adolphe de Rothschild de L’œil Et du Cerveau,Department of Clinical Epidemiology

[45] Centre Hospitalier Universitaire de Nîmes,Danish Multiple Sclerosis Centre, Department of Neurology

[46] Hôpital Carémeau,Department of Neurology

[47] Centre Hospitalier Intercommunal de Poissy Saint-Germain-en-Laye,Department of Neurology

[48] Centre Hospitalier Universitaire d’Amiens Picardie,Department of Clinical Medicine

[49] Rouen University Hospital,Department of Neurology

[50] Centre Hospitalier Universitaire Grenoble-Alpes,Central Clinical School

来源：

BMC Medical Research Methodology | / 22卷

关键词：

Effectiveness; Multiple sclerosis; Propensity score; Indication bias; Causal contrasts; Censoring; Positivity assumption;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[21] Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal
Rollot, Fabien
Couturier, Justine
Casey, Romain
Wiertlewski, Sandrine
Debouverie, Marc
Pelletier, Jean
De Seze, Jerome
Labauge, Pierre
Ruet, Aurelie
Thouvenot, Eric
Ciron, Jonathan
Berger, Eric
Gout, Olivier
Clavelou, Pierre
Stankoff, Bruno
Casez, Olivier
Bourre, Bertrand
Zephir, Helene
Moreau, Thibault
Lebrun-Frenay, Christine
Maillart, Elisabeth
Edan, Gilles
Neau, Jean-Philippe
Montcuquet, Alexis
Cabre, Philippe
Camdessanche, Jean-Philippe
Defer, Gilles
Ben Nasr, Haifa
Maurousset, Aude
Hankiewicz, Karolina
Pottier, Corinne
Leray, Emmanuelle
Vukusic, Sandra
Laplaud, David-Axel
NEUROTHERAPEUTICS, 2022, 19 (02) : 476 - 490
[22] Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis
Lorscheider, Johannes
Benkert, Pascal
Lienert, Carmen
Hanni, Peter
Derfuss, Tobias
Kuhle, Jens
Kappos, Ludwig
Yaldizli, Ozgur
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (06) : 777 - 785
[23] Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis A Registry-Based Study
Spelman, Tim
Simoneau, Gabrielle
Hyde, Robert
Kuhelj, Robert
Alroughani, Raed
Ozakbas, Serkan
Karabudak, Rana
Yamout, Bassem I.
Khoury, Samia J.
Terzi, Murat
Boz, Cavit
Horakova, Dana
Kubala Havrdova, Eva
Weinstock-Guttman, Bianca
Patti, Francesco
Altintas, Ayse
Mrabet, Saloua
Gouider, Riadh
Inshasi, Jihad
Shaygannejad, Vahid
Eichau, Sara
Ward, W. Luke
Butzkueven, Helmut
NEUROLOGY, 2024, 102 (07) : e208114
[24] Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom
Spelman, T.
Herring, W. L.
Acosta, C.
Hyde, R.
Jokubaitis, V. G.
Pucci, E.
Lugaresi, A.
Laureys, G.
Havrdova, E. K.
Horakova, D.
Izquierdo, G.
Eichau, S.
Ozakbas, S.
Alroughani, R.
Kalincik, T.
Duquette, P.
Girard, M.
Petersen, T.
Patti, F.
Csepany, T.
Granella, F.
Grand'Maison, F.
Ferraro, D.
Karabudak, R.
Jose Sa, M.
Trojano, M.
van Pesch, V.
Van Wijmeersch, B.
Cartechini, E.
Mccombe, P.
Gerlach, O.
Spitaleri, D.
Rozsa, C.
Hodgkinson, S.
Bergamaschi, R.
Gouider, R.
Soysal, A.
Prevost, J.
Garber, J.
de Gans, K.
Ampapa, R.
Simo, M.
Sanchez-Menoyo, J. L.
Iuliano, G.
Sas, A.
van der Walt, A.
John, N.
Gray, O.
Hughes, S.
De Luca, G.
JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 109 - 125
[25] NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis
Puthenparampil, Marco
Cazzola, Chiara
Zywicki, Sofia
Federle, Lisa
Stropparo, Erica
Anglani, Mariagiulia
Rinaldi, Francesca
Perini, Paola
Gallo, Paolo
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11
[26] The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis
Vollmer, Brandi
Honce, Justin M.
Sillau, Stefan
Corboy, John R.
Vollmer, Timothy
Nair, Kavita
Alvarez, Enrique
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2018, 390 : 89 - 93
[27] Natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis: a prospective observational study of 197 patients
Baroncini, D.
Ghezzi, A.
Stefanin, C.
Zaffaroni, M.
Annovazzi, P.
Baldini, S.
Comi, G.
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 191 - 192
[28] Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
Spelman, Timothy
Herring, William L.
Zhang, Yuanhui
Tempest, Michael
Pearson, Isobel
Freudensprung, Ulrich
Acosta, Carlos
Dort, Thibaut
Hyde, Robert
Havrdova, Eva
Horakova, Dana
Trojano, Maria
De Luca, Giovanna
Lugaresi, Alessandra
Izquierdo, Guillermo
Grammond, Pierre
Duquette, Pierre
Alroughani, Raed
Pucci, Eugenio
Granella, Franco
Lechner-Scott, Jeannette
Sola, Patrizia
Ferraro, Diana
Grand'Maison, Francois
Terzi, Murat
Rozsa, Csilla
Boz, Cavit
Hupperts, Raymond
Van Pesch, Vincent
Oreja-Guevara, Celia
van der Walt, Anneke
Jokubaitis, Vilija G.
Kalincik, Tomas
Butzkueven, Helmut
PHARMACOECONOMICS, 2022, 40 (03) : 323 - 339
[29] Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
Timothy Spelman
William L. Herring
Yuanhui Zhang
Michael Tempest
Isobel Pearson
Ulrich Freudensprung
Carlos Acosta
Thibaut Dort
Robert Hyde
Eva Havrdova
Dana Horakova
Maria Trojano
Giovanna De Luca
Alessandra Lugaresi
Guillermo Izquierdo
Pierre Grammond
Pierre Duquette
Raed Alroughani
Eugenio Pucci
Franco Granella
Jeannette Lechner-Scott
Patrizia Sola
Diana Ferraro
Francois Grand’Maison
Murat Terzi
Csilla Rozsa
Cavit Boz
Raymond Hupperts
Vincent Van Pesch
Celia Oreja-Guevara
Anneke van der Walt
Vilija G. Jokubaitis
Tomas Kalincik
Helmut Butzkueven
PharmacoEconomics, 2022, 40 : 323 - 339
[30] Comparison of the efficacy and retention of Natalizumab vs. Fingolimod in Cypriot patients with relapsing remitting multiple sclerosis.
Kkolou, E.
Leonidou, E.
Gaglia, E.
Pantzaris, M.
EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 198 - 198

← 1 2 3 4 5 →